Newsroom

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Mar. 28, 2017– AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) today announced that it has priced an underwritten public offering of 30,000,000 shares of common stock at a price to the public of $0.50 per share, before underwriting discounts, which would result in aggregate gross proceeds of approximately $15 million. All of the shares in the offering are to

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Mar. 22, 2017– AVEO Oncology (NASDAQ:AVEO) today announced that the first patient has been dosed in the Phase 1/2 AVEO-sponsored TiNivo trial evaluating tivozanib in combination with Bristol-Myers Squibb’s anti-PD-1 therapy, Opdivo® (nivolumab), in advanced renal cell carcinoma (RCC). The study, which will be led by the Institut Gustave Roussy in Paris, is under the

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Mar. 22, 2017– AVEO Oncology (NASDAQ:AVEO) today reported financial results for the full year ended December 31, 2016 and provided a business update. “TIVO-3, our lead clinical program designed to serve as the basis for a potential U.S. registration for tivozanib as a first- and third-line treatment for renal cell cancer, continues to enroll

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Feb. 23, 2017– AVEO Oncology (NASDAQ:AVEO) today announced that its pivotal, Phase 3 TIVO-3 trial, a randomized, controlled, multi-center, open-label study to compare tivozanib to sorafenib in subjects with refractory advanced renal cell carcinoma (RCC), has successfully completed the first safety review by the study’s Safety Monitoring Committee (SMC). The SMC concluded that no

Download PDF – Pivotal TIVO-3 Trial Enrollment Proceeding Substantially Ahead of Schedule; Enrollment Completion Expected in June – – Phase 1/2 TiNivo Trial Sites Scheduled to Open for Enrollment in Early March – – Partner EUSA Pharma Receives Day 180 List of Outstanding Issues from EMA, Oral Explanation Expected in 2Q 2017 – CAMBRIDGE, Mass.–(BUSINESS

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Feb. 6, 2017– AVEO Oncology (NASDAQ:AVEO) today announced that Michael Needle, M.D., Chief Medical Officer, will present at the 19th Annual BIO CEO & Investor Conference on Monday, February 13, 2017 at 8:30 AM E.T. at the Waldorf Astoria Hotel in New York City. A live webcast can be accessed by visiting the investors section of the Company’s website at www.aveooncology.com. A

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Nov. 28, 2016– AVEO Oncology (NASDAQ:AVEO) today announced that its development partner, EUSA Pharma, a specialty pharmaceutical company with a focus on oncology and oncology supportive care, has submitted its responses to the European Medicines Agency (EMA) Day 120 List of Questions. The Day 120 List of Questions were issued by the Committee for Medicinal Products

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Nov. 22, 2016– AVEO Oncology (NASDAQ:AVEO) today announced that Michael Bailey, president and chief executive officer, will present at the 28th Annual Piper Jaffray Healthcare Conference on Wednesday, November 30, 2016 at 3:30 PM Eastern Time. The conference is being held at the New York Palace Hotel. A live webcast can be accessed by visiting the investors section of the Company’s